Advertisement

Cost and clinical utility of repeated syphilis screening in the third trimester in a high-risk population

Published:December 12, 2013DOI:https://doi.org/10.1016/j.ajog.2013.12.012

      Objective

      We sought to determine the clinical utility and cost of repeating syphilis testing in the third trimester of pregnancy in a high-risk urban population.

      Study Design

      A retrospective cohort analysis was performed for patients delivering from January 1993 through December 2009 with at least 1 venereal disease research laboratory (VDRL) test sent during pregnancy. Chart review was performed for patients with confirmed syphilis to determine the temporal relationship of syphilis diagnosis to the pregnancy. For patients who seroconverted during pregnancy (no antecedent history or treatment for syphilis), newborn charts were reviewed. The costs of treating seropositive neonates and the costs of implementing additional third-trimester syphilis screening were then compared.

      Results

      In the 17-year cohort, 58,569 deliveries were available for analysis. In all, 113 new cases of syphilis occurred (192.9/100,000 deliveries). There were 17 detected seroconversions; 10 were not rescreened in the third trimester and tested positive at delivery. These 10 patients may have benefitted from implementing uniform VDRL testing at 28-32 weeks' gestation. All newborns were asymptomatic with a negative workup and received empiric penicillin therapy. Based on 2011 hospital charges, the cost of evaluating and treating a neonate for syphilis is $11,079. Implementing an additional VDRL screen at 28-32 weeks' gestation for each pregnant patient during the 17 years studied would cost $1,991,346. An 18-fold increase in syphilis prevalence (3500/100,000 [3.5%] deliveries) would be required for the cost of implementation of universal early third-trimester screening to be equal to the potential health care charges saved by detecting maternal seroconversion and obviating the need for neonatal therapy.

      Conclusion

      In this high-risk population, additional syphilis screening in the third trimester is costly and is not clinically helpful in detecting maternal seroconversion.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Centers for Disease Control and Prevention. Syphilis surveillance annual report (all years). Available at: http://www.cdc.gov/std/syphilis/stats.htm. Accessed July 1, 2013.

      2. Ohio Department of Health. Total syphilis statistical summaries 2012. Available at: http://www.odh.ohio.gov/healthStats/disease/std/std1.aspx. Accessed July 1, 2013.

        • Wolff T.
        • Shelton E.
        • Sessions C.
        • Miller T.
        Screening for syphilis infection in pregnant women: evidence for the US Preventive Services Task Force reaffirmation recommendation statement.
        Ann Intern Med. 2009; 150: 710-716
        • Edwards R.K.
        • Bennett M.
        • Langstrat C.
        • Greene D.
        Assessment of the value of rescreening for syphilis in the third trimester of pregnancy.
        Infect Dis Obstet Gynecol. 2006; 2006: 56504
        • Owusu-Edusei Jr., K.
        • Introcaso C.E.
        • Chesson H.W.
        Hospitalization cost of congenital syphilis diagnosis from insurance claims data in the United States.
        Sex Transm Dis. 2013; 40: 226-229
        • Patel S.J.
        • Klinger E.J.
        • O'Toole D.
        • Schillinger J.A.
        Missed opportunities for preventing congenital syphilis infection in New York City.
        Obstet Gynecol. 2012; 120: 882-888
        • Rodriquez C.S.
        • Guimaraes M.D.C.
        • Cesar C.C.
        Missed opportunities for congenital syphilis and HIV perinatal transmission prevention.
        Rev Saude Publica. 2008; 42: 851-858
        • Schrag S.J.
        • Arnold K.E.
        • Mohle-Boetani J.C.
        • et al.
        Prenatal screening for infectious diseases and opportunities for prevention.
        Obstet Gynecol. 2003; 102: 753-760
        • Warner L.
        • Rochat R.W.
        • Fichtner R.R.
        • Stoll B.J.
        • Nathan L.
        • Toomey K.E.
        Missed opportunities for congenital syphilis prevention in an urban southeastern hospital.
        Sex Transm Dis. 2011; 28: 92-98